Skip to main content
San Francisco homeNews home
Story

Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise; Here's Why - Investor's Business Daily

Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise; Here's Why  Investor's Business Daily Pfizer’s modest 2026 outlook shows its big investments will take time to pay off  CNBC Tepid 2026 outlook dents Pfizer shares  Yahoo Finance Pfizer’s stock drops after drug giant lowers its revenue forecast  MarketWatch Pfizer's 2026 guidance weighed down by lower COVID-19 product sales  FirstWord Pharma

Latest News